CNST stock forecast
Our latest prediction for Constellation Pharmaceuticals, Inc.'s stock price was made on the Dec. 13, 2019 when the stock price was at 39.38$.
In the short term (2weeks), CNST's stock price should underperform the market by -5.43%. During that period the price should oscillate between -12.86% and +10.93%.
In the medium term (3months), CNST's stock price should underperform the market by -16.59%. During that period the price should oscillate between -40.96% and +22.97%.Get email alerts
About Constellation Pharmaceuticals, Inc.
Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The company utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product candidates include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -1.93$ per share.
The book value per share is 2.60$
Three months stock forecastDec. 13, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|